CDX
DMS 114
Tumor indication
Lung
Tumor subtype
SCLC
Description
DMS 114 (Small Cell Lung Cancer CDX Model)
The DMS 114 small cell lung cancer line was derived from a patient with SCLC. It is characterized by neuroendocrine features typical of this aggressive cancer subtype. The model provides a reproducible platform for drug testing in small cell lung cancer. Its consistent growth makes it useful for translational research in oncology.
Key Features:
- Derived from human small cell lung carcinoma.
- Neuroendocrine morphology.
- Highly tumorigenic in xenografts.
- Represents aggressive SCLC biology.
Applications:
DMS 114 is applied in drug discovery programs for SCLC. It supports evaluation of cytotoxic and targeted therapies in this disease setting. Researchers use it to study neuroendocrine tumor mechanisms and biomarkers. Its robust growth provides reproducibility for preclinical pipelines.
Details
- Tumor indication
- Lung
- Tumor subtype
- SCLC
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.